Clinical Trials Browser

Phase 1/2 × Capecitabine × Breast × Clear all

NCT06324357 2026-03-18

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

Phase 1/2 Recruiting

BreastGastrointestinal

Adenocarcinoma Of Esophagus, Breast Neoplasms, Colorectal Neoplasms

NCT03424005 2026-03-16

Morpheus-panBC

Phase 1/2 Recruiting

Breast Neoplasms

NCT06134375 2026-03-12

A Study of Tetrathiomolybdate (TM) Plus Capecitabine

Phase 1/2 Recruiting

Neoplasm, Residual, Triple Negative Breast Neoplasms

NCT07007559 2026-02-03

ASPEN-09

Phase 1/2 Recruiting

Breast Neoplasms, Neoplasm Metastasis

NCT04711824 2025-12-23

SOLARA

Phase 1/2 Recruiting

Brain Neoplasms, Breast Neoplasms

NCT06247995 2025-11-06

NeoB-Cap1

Phase 1/2 Recruiting

Breast Neoplasms, Neoplasm Metastasis

NCT01349088 2025-05-02

Investigational Drug in Combination With Two Chemotherapy Drugs in Women With Locally Recurrent or Metastatic Breast Cancer

Phase 1/2 Withdrawn

Breast Neoplasms

NCT03377387 2025-04-15

Capecitabine 7/7 Schedule With Neratinib in Patients With Metastatic HER2-Positive Breast Cancer

Phase 1/2 Active not recruiting

Breast Neoplasms

NCT02734290 2025-03-10

Standard of Care Chemotherapy Plus Pembrolizumab for Breast Cancer

Phase 1/2 Active not recruiting

29 enrolled 12 charts

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT03997968 2024-12-24

A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors

Phase 1/2 Completed

BreastGastrointestinalGynecologicHead & NeckLymphoidPlasma cellSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Head and Neck Neoplasms, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Sarcoma, Lymphoma, Mantle-Cell, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT04276493 2024-12-06

Anti-HER2 Bispecific Antibody Zanidatamab (ZW25) Activity in Combination With Chemotherapy With/Without Tislelizumab

Phase 1/2 Completed

BreastGastrointestinal

Breast Neoplasms, Stomach Neoplasms

NCT03387085 2024-08-09

QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.

Phase 1/2 Terminated

9 enrolled 18 charts

Triple Negative Breast Neoplasms

NCT06202261 2024-03-12

A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer

Phase 1/2 Recruiting

Breast Neoplasms

NCT03853707 2024-02-20

Ipatasertib in Combination With Carboplatin, Carboplatin/Paclitaxel, or Capecitabine/Atezolizumab in Treating Patients With Metastatic Triple Negative Breast Cancer

Phase 1/2 Completed

28 enrolled 12 charts

Triple Negative Breast Neoplasms

NCT05845138 2023-08-01

A Study of SHR-A1811 Combined With Capecitabine in Treatment of Unresectable or Metastatic Breast Cancer With Low HER2 Expression.

Phase 1/2 Unknown

Breast Neoplasms

NCT05091528 2022-08-18

A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers

Phase 1/2 Terminated

2 enrolled 9 charts

BreastGastrointestinalThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Stomach Neoplasms, Colorectal Neoplasms

NCT03805399 2022-08-10

FUTURE

Phase 1/2 Unknown

Triple Negative Breast Neoplasms

NCT01323530 2021-01-11

A Confirmation Study of Eribulin in Combination With Capecitabine

Phase 1/2 Completed

76 enrolled 24 charts

Breast Neoplasms

NCT01326481 2019-03-18

TRC105

Phase 1/2 Completed

19 enrolled 9 charts

Breast Neoplasms

NCT02297230 2018-10-15

Locally Advanced Breast Cancer: Individualized Treatment Based On Tumor Molecular Characteristics

Phase 1/2 Terminated

44 enrolled 6 charts

Breast Neoplasms

NCT00741260 2018-09-05

Study Evaluating The Combination Of Neratinib And Capecitabine In Solid Tumors And Breast Cancer

Phase 1/2 Completed

105 enrolled 19 charts

Breast Neoplasms, Neoplasm Metastasis

NCT01132664 2016-08-17

Phase 1b/2 Study of BKM120 Plus Trastuzumab in Patients With HER2-positive Breast Cancer

Phase 1/2 Terminated

72 enrolled 15 charts

Brain Neoplasms, Breast Neoplasms

NCT00327743 2016-05-18

Combination Study of a New Taxane and Capecitabine in Patients With Metastatic Breast Cancer

Phase 1/2 Completed

Breast Neoplasms, Neoplasms

NCT00468585 2016-01-22

Study of Biweekly Capecitabine Dosing With Bevacizumab for the Treatment of Metastatic Breast Cancer Based Upon the Norton-Simon Mathematical Model

Phase 1/2 Completed

62 enrolled 9 charts

Breast Neoplasms, Neoplasm Metastasis

NCT00070252 2015-05-04

Neoadjuvant Tipifarnib, Docetaxel, and Capecitabine in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIA or Stage IIIB Breast Cancer

Phase 1/2 Completed

Breast Neoplasms, Breast Neoplasms, Male, Inflammatory Breast Neoplasms

NCT00037609 2012-10-24

Safety, Efficacy and Pharmacokinetic Between Capecitabine and Exisulind in Metastatic Breast Cancer Patients

Phase 1/2 Completed

Breast Neoplasms, Neoplasm Metastasis

NCT00003902 2012-05-15

Capecitabine and Vinorelbine in Treating Older Women Who Have Metastatic Breast Cancer With or Without Bone Involvement

Phase 1/2 Completed

Breast Neoplasms

NCT00031876 2012-05-15

Capecitabine and Paclitaxel in Treating Patients With Metastatic Breast Cancer

Phase 1/2 Completed

Breast Neoplasms

NCT00006108 2012-02-07

Capecitabine, Paclitaxel, and Trastuzumab in Treating Patients With Metastatic Breast Cancer

Phase 1/2 Completed

Breast Neoplasms

NCT00324610 2006-05-18

Tolerance and Pharmacokinetics With Capecitabine 5 Out of 7 Days Regimen

Phase 1/2 Unknown

Breast Neoplasms, Neoplasm Metastasis